First Oral JAK Inhibitor Approved for Severe Alopecia Areata in Teens
The FDA approved the Janus kinase (JAK) inhibitor ritlecitinib (Litfulo) for…
Browsing Tag
JAK
Phase II Study: Bispecific Oral Drug Tops Leading JAK Inhibitor for RA
MILAN -- A novel oral agent that blocks two different kinase enzymes was possibly more effective against…
JAK Inhibitor Shows Promise in Severe Type of Sclerosis
The Janus kinase (JAK) inhibitor ruxolitinib (Jakafi) eased the severe…
First JAK Inhibitor Approved for Crohn’s Disease
The FDA approved upadacitinib (Rinvoq) for treating Crohn's disease,…
Another Win for a JAK Inhibitor in Alopecia Areata
NEW ORLEANS -- Patients with severe alopecia areata had dramatic hair regrowth at 6 months with an investigational Janus kinase…
JAK Inhibitor Succeeds in Refractory Vasculitis
Patients with treatment-resistant granulomatosis with polyangiitis (GPA) may see improvement…
JAK Inhibitor Improves Symptoms, Anemia in Myelofibrosis
Myelofibrosis treatment with the Janus kinase (JAK) inhibitor momelotinib resulted in clinically significant improvements in…
JAK Inhibitor Promising for Polymyalgia Rheumatica
Tofacitinib (Xeljanz) appeared highly effective against polymyalgia rheumatica (PMR) in a…
No Special Heart Risk With JAK Inhibitors, Study Finds
Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar…
Brighter Future for Treatment of Alopecia Areata
The medication, made by Eli Lilly, is called baricitinib, part of the Janus kinase (JAK) inhibitor class. Two other JAK inhibitors for the condition (one from Pfizer and another from Concert…